Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV1 molecular glue
Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV1 molecular glue